HSBC says this biopharma company can jump 25% despite 'patent cliff'

  • 📰 CNBC
  • ⏱ Reading Time:
  • 5 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 5%
  • Publisher: 72%

Colombia Noticias Noticias

Colombia Últimas Noticias,Colombia Titulares

HSBC initiated coverage on the drug treatment developer with a buy rating.

Its price target of $320 suggests shares could rally 25% from Tuesday's close. "Amgen is a best-in-class operator with high margins and a strong history of protecting its assets. While some very old products are finally facing patent cliffs it will likely be gradual and a broadened portfolio allows for continued growth," analyst Morten Herholdt wrote in a Wednesday note.

mountain AMGN in 2023 — CNBC's Michael Bloom contributed to this report.

Hemos resumido esta noticia para que puedas leerla rápidamente. Si estás interesado en la noticia, puedes leer el texto completo aquí. Leer más:

 /  🏆 12. in CO
 

Gracias por tu comentario. Tu comentario será publicado después de ser revisado.

Colombia Últimas Noticias, Colombia Titulares